Skip to main content
SAREUM HOLDINGS PLC logo

SAREUM HOLDINGS PLC — Investor Relations & Filings

Ticker · SAR ISIN · GB00BMC3RJ87 LEI · 213800PKERN2DY8FFM72 IL Manufacturing
Open in API
Filings indexed 348 across all filing types
Latest filing 2022-07-04 Regulatory Filings
Country GB United Kingdom
Listing IL SAR

About SAREUM HOLDINGS PLC

https://www.sareum.com/

Sareum Holdings PLC is a clinical-stage small molecule company that discovers and develops next-generation kinase inhibitors for the treatment of autoimmune diseases and cancer. The company's research is primarily focused on the TYK/JAK kinase cell signalling family, with a specific emphasis on developing dual inhibitors of TYK2 and JAK1. This approach is pursued for its potential to offer superior efficacy compared to agents that target only one of these kinases. Its development pipeline includes SDC-1801, a potential oral therapy for autoimmune diseases, as well as other programs targeting cancer and viral infections.

Recent filings

Filing Released Lang Actions
Sareum notes GSK's completed acquisition of Sierra
Regulatory Filings Classification · 99% confidence The document is identified by the header 'RNS Number : 1195R' and contains information about a corporate event (GSK's acquisition of Sierra Oncology, which impacts Sareum's licensing rights). The text concludes with standard disclaimers from RNS, the news service of the London Stock Exchange, stating that 'This information is provided by RNS, the news service of the London Stock Exchange.' This strongly indicates a general regulatory announcement disseminated via the RNS system, which corresponds to the 'Regulatory Filings' category, as it is not a specific financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A). Since it is a general, timely announcement distributed through the official regulatory news service, RNS is the most appropriate classification.
2022-07-04 English
Sareum to Present at BioTrinity 2022 Conference
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and is dated April 26, 2022. The content announces that the CEO will give a 'Company Showcase presentation' at the BioTrinity 2022 conference and provides details about the presentation content and where a video copy will be available. This is a general announcement to the market regarding corporate activity (presenting at a conference) and is distributed via RNS, the news service of the London Stock Exchange. Since it is not a full report (like 10-K or IR) but a brief announcement of an event/update, and it is explicitly distributed via RNS, the most appropriate classification is Regulatory Filings (RNS), as it serves as a general regulatory disclosure that doesn't fit the more specific categories like ER, IP, or DIV. The document length (4801 chars) is short enough to suggest it's an announcement rather than a full report.
2022-04-26 English
Sareum notes acquisition of Sierra Oncology by GSK
M&A Activity Classification · 99% confidence The document is identified by the RNS Number (3162I) and the header 'RNS Number : 3162I' followed by the date and company name. RNS stands for Regulatory News Service, which is the primary mechanism for listed companies in the UK (like Sareum Holdings PLC on AIM) to disseminate material information to the market. The content itself is an announcement regarding a third-party M&A event (GSK acquiring Sierra Oncology) that impacts Sareum's licensing rights. Since this is a general, time-sensitive regulatory announcement that doesn't fit neatly into specific financial report categories (like 10-K, ER, or IR), the most appropriate classification is the general regulatory filing category.
2022-04-13 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1934 characters) and announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange, identified by the 'RNS Number : 2848I'. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report like an ER, 10-K, or IR. Since it is a general regulatory announcement that doesn't fit the specific categories (like DVA, DIV, DLST), the most appropriate fallback category is Regulatory Filings (RNS).
2022-04-13 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1917 characters) and its primary content is an announcement regarding a 'Price Monitoring Extension' for a security, referencing the 'RNS Number' and stating that the information is provided by RNS, the news service of the London Stock Exchange, which is approved by the Financial Conduct Authority (FCA). This structure—a brief notification about a market event or regulatory process, distributed via the RNS system—fits the definition of a general regulatory announcement that doesn't correspond to a specific financial report (like 10-K, ER, or IR). Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory announcements.
2022-04-13 English
European Patent Granted for Sareum’s SDC-1802
Regulatory Filings Classification · 100% confidence The document starts with 'RNS Number' and is dated April 11, 2022. It announces a specific corporate event: the European Patent Office issuing a formal notification of grant for a patent related to the company's drug candidate SDC-1802. The text concludes with standard boilerplate language referencing RNS, the London Stock Exchange, and the Financial Conduct Authority (FCA). This structure is characteristic of a general regulatory news service announcement, which fits the definition of a Regulatory Filing (RNS) or potentially an Intellectual Property (IP) filing if the IP aspect was dominant. However, since it is a broad announcement distributed via the RNS system about a specific corporate development (patent grant), RNS is the most appropriate general category, especially given the presence of the RNS header and footer. It is not a full report (10-K, IR), a presentation (IP), or a management change (MANG).
2022-04-11 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.